A Phase 2 interventional study of MT-501 and MT-201 in Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn's Disease, sponsored by Mirador Therapeutics, Inc.. Recruiting at 66 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Mirador Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 74th largest by planned enrollment of the 327 interventional ones that give a count, is one of 30 that started in 2025, is one of 63 in phase 2, reaches primary completion later than 44 of the 121 other live ones, and was the 428th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of Michigan · Sites in United States
Ages 18+
Hope Biosciences Research Foundation · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 30 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
Mirador Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Mirador Therapeutics, Inc. has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
42 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
| NCT06065228Children's National Research InstituteTherapeutic Endpoint in Pediatric IBD Conditions | 2026-12 |
Add all 42 to your calendar (.ics) → With an account.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
The purpose of this platform study is to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) to evaluate multiple oral or parenteral experimental therapies for moderately to severely active Crohn's Disease or Ulcerative Colitis.
Inclusion Criteria-Crohn's Disease:
Inclusion Criteria-Ulcerative Colitis:
Exclusion Criteria-Crohn's Disease:
Exclusion Criteria-Ulcerative Colitis:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MT-501 Tablets
Drug: MT-501
Participants will receive MT-501Tablets
Drug: MT-501
Participants will receive multiple intravenous doses of MT-201 with standard of care
Drug: MT-201
MT-501
MT-201
Assess the proportion of participants reporting treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) leading to discontinuation, and markedly abnormal laboratory values
Time frame: Up to 13 weeks
Assess the Proportion of Participants with Endoscopic Response (CD)
Endoscopic response as assessed by SES-CD score.
Time frame: 13 weeks
Assess the Proportion of Participants Endoscopic Improvement (UC)
Endoscopic improvement as assessed by MES.
Time frame: 12 weeks
Assess the Proportion of Participants with Clinical Remission (CD)
Clinical remission as assessed by CDAI score.
Time frame: 13 weeks
Assess the Proportion of Participants with Clinical Remission (UC)
Clinical remission as assessed by endoscopy, rectal bleeding and stool frequency.
Time frame: 12 weeks
Assess the Proportion of Participants with Clinical Remission (CD)
CD: Clinical remission as assessed by CDAI score.
Time frame: 13 weeks
Assess the Proportion of Participants with Clinical Remission (UC)
Clinical remission as assessed by endoscopy, rectal bleeding, and stool frequency.
Time frame: 12 weeks
Assess the Proportion of Participants with Symptomatic Remission (CD and UC)
Symptomatic remission as assessed by patient reported outcomes.
Time frame: Up to 13 weeks
Assess the Proportion of Participants with Clinical Response (CD)
CD: Clinical response as assessed by CDAI score.
Time frame: 13 weeks
Assess the Proportion of Participants with Clinical Response (UC)
UC: Clinical response as assessed by MMCS.
Time frame: 12 weeks
Assess the Proportion of Participants with Endoscopic and Clinical Response (CD Only)
Endoscopy as assessed by SES-CD and clinical response as assessed by CDAI score.
Time frame: 13 weeks
Assess the Proportion of Participants with Histologic Response (UC Only)
Histologic response as assessed by the RHI.
Time frame: 12 weeks
Assess the Proportion of Participants with Histologic Remission (UC only)
Histologic remission as assessed by the RHI.
Time frame: 12 weeks
Assess the Proportion of Participants with Histologic-Endoscopic Mucosal Improvement (UC only)
Histologic-endoscopic mucosal improvement as assessed by the Geboes score and MES.
Time frame: 12 weeks
Characterize the Change in Endoscopy Score (CD)
CD: Endoscopy score as assessed by SES-CD.
Time frame: 13 weeks
Characterize the Change in Endoscopy Score (UC)
Endoscopy score as assessed by MES.
Time frame: 12 weeks
Characterize the Change in Histology Score (CD)
Histology as assessed by GHAS and RHI.
Time frame: 13 weeks
Characterize the Change in Histology Score (UC)
Histology as assessed by Geobes, RHI and NHI
Time frame: 12 weeks
Asses the Pharmacokinetics (PK) (e.g., Trough Concentration [Ctrough]) of Investigational Drug
Time frame: Up to 13 weeks
Assess immunogenicity
Time frame: 13 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
Of 61 phase 2 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 43. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adecatumumab
Mirador Therapeutics, Inc.